Bhalla S, Fattah FJ, Ahn C, Williams J, et al. Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer. Lung Cancer 2023;182:107291.
PMID: 37423058